RYTMRhythm Pharmaceuticals, Inc.
Price
-5.4%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, growing in the filings, the market undecided.
We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Rhythm Pharmaceuticals, Inc. (RYTM) reported revenue of $71M in Q2 2026 (quarter ended Jun 30, 2026), up 47% from the same quarter a year earlier. That came with a gross margin of 87% and net loss of $49M. For the full year FY2025, revenue was $190M (+46% year on year) and net income −$197M. Its largest region in Q2 2026 was United States at $51M, 72% of the disclosed total, well ahead of Non Us at 28%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026The presentation is available in the “Events and Presentations” portion of the Company’s website at ir.rhythmtx.com.Earnings release · Form 8-K
- Jun 15, 2026The presentation is available in the “Events and Presentations” portion of the Company’s website at ir.rhythmtx.com.Regulation FD disclosure · Form 8-K
- Apr 3, 2026Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers On April 1, 2026, the Board of Directors (the “Board”) of Rhythm Pharmaceuticals, Inc. (the “Company”) elected Kimberly J. Popovits as a non-employee director of the …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $71.3MThe company’s own SEC segment disclosure.
- United States$51.0M72%
- Non Us$20.3M28%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.